Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
The summary for the Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed): Neuroinflammation triggered by brain trauma, neurodegenerative diseases and neurotoxicant-induced CNS disorders initiates CNS innate immune responses that activate inflammasomes. Inflammasomes are high molecular weight complexes in the cytosol of stimulated immune cells that mediate the activation of inflammatory cascades. In response to insults, Nod-like receptors (NLRs) recruit adaptor proteins and caspase-1 to assemble inflammasomes and process the release of pro-inflammatory cytokines IL-1?, IL-18 and IL-33. Recent evidence suggests that chronic drug exposure, i.e., cocaine, methamphetamine and morphine, can induce inflammasome activation primarily mediated by NLRP3 within microglia. Additionally, emerging data suggest that HIV-1 infection can also prime inflammasome activation. Drug abuse, especially in association with HIV-1 infection, induces ROS production, impairs blood brain barrier integrity, and promotes monocyte transmigration. These upstream events exert synergistic effects that prime oligomerization and activation of inflammasome and release of pro-inflammatory cytokine IL-1?. The scientific objective of this research is to delineate the role of inflammasomes in neuropathology produced by chronic drug exposure and HIV infection. Understanding the involvement of inflammasome in the immune activation may help identify molecular markers and immune cells associated with HIV-1 disease progression among substance abuse populations, and identify novel targets for intervention to treat neuroinflammation and immune dysregulation aroused in these processes.
|Federal Grant Title:||Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)|
|Federal Agency Name:||National Institutes of Health (HHS-NIH11)|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-DA-19-039|
|Type of Funding:||Grant|
|CFDA Descriptions:||Information not provided|
|Current Application Deadline:||May 24th, 2019|
|Original Application Deadline:||May 24th, 2019|
|Posted Date:||April 4th, 2019|
|Creation Date:||April 4th, 2019|
|Archive Date:||June 29th, 2019|
|Total Program Funding:|
|Maximum Federal Grant Award:|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
|Last Updated:||April 5th, 2019|
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- Grant Announcement Contact
- NIH OER Webmaster
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Similar Government Grants
- • Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
- • New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Tria...
- • New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Tr...
- • NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
- • Using Human Cell Animal Chimera Brains to Study HIV Latency and Pathology R01 - Clinical T...
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...